Market Cap 7.40M
Revenue (ttm) 90,000.00
Net Income (ttm) -13.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15,511.11%
Debt to Equity Ratio 0.00
Volume 459,600
Avg Vol 3,636,074
Day's Range N/A - N/A
Shares Out 30.44M
Stochastic %K 40%
Beta 1.20
Analysts Sell
Price Target $5.25

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon produ...

Industry: Biotechnology
Sector: Healthcare
Phone: 352 448 7797
Fax: 352 480 4620
Address:
2117 SW Highway 484, Ocala, United States
Deadcandance
Deadcandance Aug. 19 at 9:19 AM
$AIM sooo much spam in here, hurts my eyes
1 · Reply
sschmid1
sschmid1 Aug. 19 at 5:44 AM
$AIM Something interesting in the Q2 institutional data for $AIM 👀 According to the publicly available 13F dataset: Q1 → Q2 2026 • Institutional holders: 17 → 19 • Reported shares: 174,893 → 1,147,385 • That’s +972K shares / ~+556% increase Reported institutional exposure increased meaningfully during the quarter. Data is publicly available here: https://13f.info/cusip/00901B303/2026/2/compare/2026/1 Worth asking: What changed in Q2 to drive this shift?
1 · Reply
Aimforsuccess
Aimforsuccess Aug. 19 at 12:08 AM
$AIM Notice how old shorty will go to great lengths to try and discredit others, but won’t show managements missteps over the past five years. When i said it wasn't about the science, he tried to change the subject or direction.
0 · Reply
sschmid1
sschmid1 Aug. 18 at 11:56 PM
$AIM For newer $AIM shareholders, one more piece of context about @Aimforsuccess. This was his first $AIM post, shortly after joining Stocktwits in February 2025: “Anyone want to step with regard to Aim, Tom, questionable financing sources, naked shorting, etc?” At the time, the suggested destination was the SEC. Fast-forward to yesterday, and we’re now talking about a “full scale FBI investigation.” Maybe next time we’ll get a different federal agency. 😂 I’m not suggesting anyone is right or wrong simply because they’ve been bearish for a long time. I’m just giving newer shareholders some context so they can judge for themselves what role and credibility they want to assign to this account.
0 · Reply
ultimatebastos
ultimatebastos Aug. 18 at 8:13 PM
$AIM https://www.yahoo.com/news/world/articles/dr-congo-ebola-outbreak-far-145236531.html
0 · Reply
Aimforsuccess
Aimforsuccess Aug. 18 at 5:31 PM
$AIM LOL. Perhaps the funniest thing i have read today is : ”Don’t rely on management.” No one has suggested that the science doesn’t work. Go back and study what management has spent money on, how compensation plans are structured, basically you decide how the company has been run for the past five years. Don’t just rely on the short’s mouthpiece.
3 · Reply
sschmid1
sschmid1 Aug. 18 at 4:51 PM
$AIM For the new $AIM shareholders this is addressed to: @Aimforsuccess suggests you go back and listen to AIM management’s statements over the last 5 years. Fair advice — but don’t stop there. Also read the many independent peer-reviewed scientific publications on Ampligen/rintatolimod and the clinical work conducted by institutions such as Erasmus, Roswell Park and others. Then decide for yourself: Is AIM management simply “spewing hype” about Ampligen? Or is there actually real independent science and clinical data behind the potential? Don’t rely on management. Don’t rely on Stocktwits bears. Read the science and make your own judgment.
2 · Reply
Aimforsuccess
Aimforsuccess Aug. 18 at 4:03 PM
$AIM For new investors, go back and listen to and read management’s statements over the last five years. You decide if they just continue to spew the same hype, over and over again . How many times has there been a reverse split and by how much? ( It’s pretty smazing, over a hundred to one? ) How many shares have traded on really busy days and how did it affect the selling price! You decide if shorts are running the company. Is this Maddoff 2.0? Would you love to see a full scale FBI investigation,
0 · Reply
elon_musk22
elon_musk22 Aug. 18 at 11:40 AM
$AIM what ever happened to this this 10 yr pumper I am old enough to remember when he blamed the naked shorts for this failed biotech just saying
1 · Reply
sschmid1
sschmid1 Aug. 18 at 1:36 AM
$AIM For newer $AIM shareholders, I’m resharing this thread as one example of how @phantajuicy and @uuddlrlr approach this ticker. We’ve seen plenty of their negative commentary over time, which is perfectly fine — everyone is entitled to be bearish. But in this case, I asked a very simple question: What is the source for presenting the old May 7 $0.48 warrant exercise as a new financing? Days later: still no answer, no filing, no source. Both repeatedly describe themselves as $AIM shareholders, so I’ll let newer readers look at the original post/thread and decide for themselves how much weight they want to give these accounts. 😏
1 · Reply
Latest News on AIM
AIM ImmunoTech Quarterly report: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 12 days ago

AIM ImmunoTech Quarterly report: Q2 2026


AIM ImmunoTech Earnings release: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 12 days ago

AIM ImmunoTech Earnings release: Q2 2026


AIM ImmunoTech Proxy statement: Proxy filing

Jun 25, 2026, 8:00 AM EDT - 7 weeks ago

AIM ImmunoTech Proxy statement: Proxy filing


AIM ImmunoTech Registration statement: Registration filing

Jun 18, 2026, 8:00 AM EDT - 2 months ago

AIM ImmunoTech Registration statement: Registration filing


AIM ImmunoTech Proxy statement: Proxy filing

Jun 15, 2026, 8:00 AM EDT - 2 months ago

AIM ImmunoTech Proxy statement: Proxy filing


AIM ImmunoTech Inc trading resumes

2026-06-09T13:50:10.000Z - 2 months ago

AIM ImmunoTech Inc trading resumes


AIM ImmunoTech announces $2.65M registered direct offering

2026-06-09T13:41:34.000Z - 2 months ago

AIM ImmunoTech announces $2.65M registered direct offering


AIM ImmunoTech Inc trading halted, news pending

2026-06-09T13:29:35.000Z - 2 months ago

AIM ImmunoTech Inc trading halted, news pending


AIM ImmunoTech Registration statement: Registration filing

Jun 8, 2026, 8:00 AM EDT - 2 months ago

AIM ImmunoTech Registration statement: Registration filing


3 Penny Stocks Drawing Market Attention, 6/2/26

2026-06-02T17:36:51.000Z - 2 months ago

3 Penny Stocks Drawing Market Attention, 6/2/26

ANY HKIT


AIM ImmunoTech Inc trading resumes

2026-05-20T19:20:11.000Z - 3 months ago

AIM ImmunoTech Inc trading resumes


AIM ImmunoTech announces $2.4M registered direct offering

2026-05-20T19:10:27.000Z - 3 months ago

AIM ImmunoTech announces $2.4M registered direct offering


AIM ImmunoTech Inc trading halted, news pending

2026-05-20T19:00:12.000Z - 3 months ago

AIM ImmunoTech Inc trading halted, news pending


CMMI Institute Completes Pilot for New AI Maturity (AIM) Framework

May 19, 2026, 11:41 AM EDT - 3 months ago

CMMI Institute Completes Pilot for New AI Maturity (AIM) Framework


AIM ImmunoTech Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

AIM ImmunoTech Quarterly report: Q1 2026


AIM ImmunoTech Transcript: Virtual Investor Closing Bell

Apr 16, 2026, 4:00 PM EDT - 4 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell


AIM ImmunoTech Provides Routine Update on Annual Filings

Apr 13, 2026, 6:00 PM EDT - 4 months ago

AIM ImmunoTech Provides Routine Update on Annual Filings


AIM ImmunoTech Annual report: Q4 2025

Mar 27, 2026, 4:00 PM EDT - 5 months ago

AIM ImmunoTech Annual report: Q4 2025


Biotech Alert: Searches spiking for these stocks today

2026-03-20T14:55:28.000Z - 5 months ago

Biotech Alert: Searches spiking for these stocks today


Why Is AIM ImmunoTech Stock (AIM) Up Today?

2026-03-18T13:47:09.000Z - 5 months ago

Why Is AIM ImmunoTech Stock (AIM) Up Today?


AIM announces approval of patent for Ampligen in Japan

2026-03-18T12:51:46.000Z - 5 months ago

AIM announces approval of patent for Ampligen in Japan


AIM ImmunoTech Announces Closing of its Rights Offering

Mar 6, 2026, 7:00 PM EST - 5 months ago

AIM ImmunoTech Announces Closing of its Rights Offering


Biotech Alert: Searches spiking for these stocks today

2026-03-04T15:25:35.000Z - 5 months ago

Biotech Alert: Searches spiking for these stocks today


AIM ImmunoTech announces preliminary results of rights offering

2026-03-04T14:05:33.000Z - 5 months ago

AIM ImmunoTech announces preliminary results of rights offering


AIM ImmunoTech extends subscription period of rights offering

2026-02-25T14:19:06.000Z - 6 months ago

AIM ImmunoTech extends subscription period of rights offering


AIM ImmunoTech Transcript: Virtual Investor Closing Bell

Feb 19, 2026, 4:00 PM EST - 6 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell


AIM ImmunoTech Transcript: Corporate Connect Webinar Series

Feb 11, 2026, 1:40 PM EST - 6 months ago

AIM ImmunoTech Transcript: Corporate Connect Webinar Series


AIM ImmunoTech Announces Commencement of Rights Offering

Feb 11, 2026, 8:30 AM EST - 6 months ago

AIM ImmunoTech Announces Commencement of Rights Offering


AIM ImmunoTech Registration statement: Registration Filing

Feb 10, 2026, 7:00 AM EST - 6 months ago

AIM ImmunoTech Registration statement: Registration Filing


AIM ImmunoTech Slides: Corporate presentation

Feb 4, 2026, 7:00 AM EST - 7 months ago

AIM ImmunoTech Slides: Corporate presentation


AIM ImmunoTech Registration statement: Registration Filing

Jan 29, 2026, 7:00 AM EST - 7 months ago

AIM ImmunoTech Registration statement: Registration Filing


AIM ImmunoTech Registration statement: Registration filing

Jan 23, 2026, 7:00 AM EST - 7 months ago

AIM ImmunoTech Registration statement: Registration filing


AIM ImmunoTech Transcript: AGM 2025

Dec 16, 2025, 11:00 AM EST - 8 months ago

AIM ImmunoTech Transcript: AGM 2025


AIM ImmunoTech Transcript: Virtual Investor Closing Bell Series

Dec 4, 2025, 4:00 PM EST - 9 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell Series


AIM ImmunoTech Quarterly report: Q3 2025

Nov 17, 2025, 4:00 PM EST - 9 months ago

AIM ImmunoTech Quarterly report: Q3 2025


AIM ImmunoTech Proxy statement: Proxy Filing

Oct 29, 2025, 8:30 AM EDT - 10 months ago

AIM ImmunoTech Proxy statement: Proxy Filing


AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

Oct 20, 2025, 9:15 AM EDT - 10 months ago

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit


AIM ImmunoTech Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

AIM ImmunoTech Quarterly report: Q2 2025


AIM ImmunoTech Earnings release: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

AIM ImmunoTech Earnings release: Q2 2025


AIM ImmunoTech Resumes Trading on NYSE American

Jun 17, 2025, 8:55 AM EDT - 1 year ago

AIM ImmunoTech Resumes Trading on NYSE American


AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Jun 11, 2025, 4:15 PM EDT - 1 year ago

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split


Deadcandance
Deadcandance Aug. 19 at 9:19 AM
$AIM sooo much spam in here, hurts my eyes
1 · Reply
sschmid1
sschmid1 Aug. 19 at 5:44 AM
$AIM Something interesting in the Q2 institutional data for $AIM 👀 According to the publicly available 13F dataset: Q1 → Q2 2026 • Institutional holders: 17 → 19 • Reported shares: 174,893 → 1,147,385 • That’s +972K shares / ~+556% increase Reported institutional exposure increased meaningfully during the quarter. Data is publicly available here: https://13f.info/cusip/00901B303/2026/2/compare/2026/1 Worth asking: What changed in Q2 to drive this shift?
1 · Reply
Aimforsuccess
Aimforsuccess Aug. 19 at 12:08 AM
$AIM Notice how old shorty will go to great lengths to try and discredit others, but won’t show managements missteps over the past five years. When i said it wasn't about the science, he tried to change the subject or direction.
0 · Reply
sschmid1
sschmid1 Aug. 18 at 11:56 PM
$AIM For newer $AIM shareholders, one more piece of context about @Aimforsuccess. This was his first $AIM post, shortly after joining Stocktwits in February 2025: “Anyone want to step with regard to Aim, Tom, questionable financing sources, naked shorting, etc?” At the time, the suggested destination was the SEC. Fast-forward to yesterday, and we’re now talking about a “full scale FBI investigation.” Maybe next time we’ll get a different federal agency. 😂 I’m not suggesting anyone is right or wrong simply because they’ve been bearish for a long time. I’m just giving newer shareholders some context so they can judge for themselves what role and credibility they want to assign to this account.
0 · Reply
ultimatebastos
ultimatebastos Aug. 18 at 8:13 PM
$AIM https://www.yahoo.com/news/world/articles/dr-congo-ebola-outbreak-far-145236531.html
0 · Reply
Aimforsuccess
Aimforsuccess Aug. 18 at 5:31 PM
$AIM LOL. Perhaps the funniest thing i have read today is : ”Don’t rely on management.” No one has suggested that the science doesn’t work. Go back and study what management has spent money on, how compensation plans are structured, basically you decide how the company has been run for the past five years. Don’t just rely on the short’s mouthpiece.
3 · Reply
sschmid1
sschmid1 Aug. 18 at 4:51 PM
$AIM For the new $AIM shareholders this is addressed to: @Aimforsuccess suggests you go back and listen to AIM management’s statements over the last 5 years. Fair advice — but don’t stop there. Also read the many independent peer-reviewed scientific publications on Ampligen/rintatolimod and the clinical work conducted by institutions such as Erasmus, Roswell Park and others. Then decide for yourself: Is AIM management simply “spewing hype” about Ampligen? Or is there actually real independent science and clinical data behind the potential? Don’t rely on management. Don’t rely on Stocktwits bears. Read the science and make your own judgment.
2 · Reply
Aimforsuccess
Aimforsuccess Aug. 18 at 4:03 PM
$AIM For new investors, go back and listen to and read management’s statements over the last five years. You decide if they just continue to spew the same hype, over and over again . How many times has there been a reverse split and by how much? ( It’s pretty smazing, over a hundred to one? ) How many shares have traded on really busy days and how did it affect the selling price! You decide if shorts are running the company. Is this Maddoff 2.0? Would you love to see a full scale FBI investigation,
0 · Reply
elon_musk22
elon_musk22 Aug. 18 at 11:40 AM
$AIM what ever happened to this this 10 yr pumper I am old enough to remember when he blamed the naked shorts for this failed biotech just saying
1 · Reply
sschmid1
sschmid1 Aug. 18 at 1:36 AM
$AIM For newer $AIM shareholders, I’m resharing this thread as one example of how @phantajuicy and @uuddlrlr approach this ticker. We’ve seen plenty of their negative commentary over time, which is perfectly fine — everyone is entitled to be bearish. But in this case, I asked a very simple question: What is the source for presenting the old May 7 $0.48 warrant exercise as a new financing? Days later: still no answer, no filing, no source. Both repeatedly describe themselves as $AIM shareholders, so I’ll let newer readers look at the original post/thread and decide for themselves how much weight they want to give these accounts. 😏
1 · Reply
mcBitchin
mcBitchin Aug. 17 at 9:32 PM
$AIM sleeper but reported $9.9m in cash for Ampligen and Ebola outbreak is making it bullish to grab onto now
0 · Reply
PhilipBio
PhilipBio Aug. 17 at 5:33 PM
$AIM time is ticking, prob continuing today during trading hours and after hours / overnight/ pre market tomorrow 💥
0 · Reply
Tesla475
Tesla475 Aug. 17 at 5:12 PM
$AIM 🙏🏼
0 · Reply
PhilipBio
PhilipBio Aug. 17 at 5:06 PM
$AIM waiting for the run, also w ebola news it should be popping soon
0 · Reply
ultimatebastos
ultimatebastos Aug. 17 at 7:35 AM
$AIM https://aimimmuno.com/aim-immunotech-ceo-highlights-biodefense-and-military-force-protection-in-newly-published-breaking-defense-article/
0 · Reply
ultimatebastos
ultimatebastos Aug. 17 at 7:32 AM
$AIM https://www.fodmapeveryday.com/deadly-ebola-outbreak-kills-over-2000-what-americans-need-to-know/
0 · Reply
RCInvestor
RCInvestor Aug. 17 at 6:22 AM
P3 premarket $UUU $AIM $MCRP $SRXH related to $SMTK
0 · Reply
RCInvestor
RCInvestor Aug. 17 at 6:03 AM
P2 premarket watch $AIM $PHGE $PLAG
0 · Reply
fatpie68
fatpie68 Aug. 16 at 12:30 PM
I'm not worried about warrants getting exercised at a reduced price. With this latest ER, $AIM ROIC improved 360.8%, D/E improved 1.65, CPS increased $0.12, and Institutional Ownership increased 3.09%. The EPS QoQ for Q1 was +86.80 and for Q2 was +93.98 - both significant increases and trending up. Point being, there's a lot to like here and the real prize comes in December with the Clinical Benefit Rate being submitted for the Ampligen/Imfinzi Combo.
1 · Reply
sschmid1
sschmid1 Aug. 16 at 11:27 AM
$AIM @phantajuicy @uuddlrlr A genuine question for both of you, especially given your repeated statements that you are $AIM shareholders. @phantajuicy recently described himself as a “long-term investor with a significant investment.” So why have neither of you addressed the $0.48 financing post after I asked for the source? The post presented the reduced-price warrant exercise as a recent financing announcement. But that transaction was announced by AIM on May 7, 2026, months ago. I’ve asked for the SEC filing or company announcement supposedly supporting a new financing. Still nothing. If you’re both genuinely significant shareholders, shouldn’t getting this kind of information right be in your own interest? At the very least, @phantajuicy, why not simply say: “You’re right, I was referring to the May 7 financing”? That would be perfectly reasonable. But continuing to leave an old financing presented as new, while neither of you provides a source, is a very different story.
0 · Reply
ultimatebastos
ultimatebastos Aug. 16 at 10:00 AM
$AIM no matter how you look at it the financial criminals just can not afford AIM to make it. That’s why they keep up their ferocious crimes so tight.
0 · Reply
jonjonson1234
jonjonson1234 Aug. 15 at 10:38 AM
$AIM From the last 10-Q: "The Company’s net loss for the quarter ended June 30, 2026 was $3.8 million compared with a net loss of $2.8 million for the quarter ended June 30, 2025, an increase of $1.0 million. The increase in net loss was primarily attributable to offering related costs incurred in connection with multiple equity transactions completed during the quarter, including placement agent fees, legal fees, accounting fees, and other direct transaction costs, as discussed below. Total costs and expenses increased to $3.5 million for the quarter ended June 30, 2026, compared with $2.7 million for the quarter ended June 30, 2025, an increase of approximately 32.5%." The did a lot of dilution to raise capital to meet listing standards this year. But, if their losses and cash burn persist, it will not be long before they have to do more dilution. And, if the share price nears 0.10, they will do the reverse-split that was approved in the recent vote.
1 · Reply